
Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Growth-hormone fragment
HGH Fragment 176-191
In stock
A C-terminal growth-hormone fragment used in sequence and pathway studies.
Order within — · ships today Cutoff 10:00 · local time
Arrives Sep 21 - Sep 23 to Europe
HGH Fragment 176-191
Price range: 55,50 € through 77,00 €
hGH C-terminal fragment for structure-function and metabolic pathway studies.
Scroll horizontally to reach every product-information tab.
Research overview
HGH Fragment 176-191
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone.
Research uses the fragment in sequence-function comparisons and metabolic-signalling models distinct from the full-length protein. The listed sources are a research starting point rather than a substitute for product evidence: the supplied material's exact form, lot, and measured characteristics must be established through its signed analytical record.
Compound information
Specifications
Molecular profile
- Sequence
- Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (hGH 176-191; disulfide Cys7-Cys14)
- Molecular mass
- 1799.1 g/mol
- CAS number
- 66004-57-7
- Molecular formula
- C78H123N23O22S2
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Synthetic hGH fragment research compound; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Latest test results
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 5mg

98.3%Purity by HPLC
Recorded QC panel
- AssayPeptide Screening 0.1% TFA
- 4.41 mg (± 0.02 mg)
- PurityPeptide Screening 0.1% TFA
- 98.3%
- Identity (FTIR)Peptide Screening 0.1% TFA
- 967 (± 5)
- Identity (RT)Retention time
- 0.995 (± 0.005)
- Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
- 0.330 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

99.4%Purity by HPLC
Recorded QC panel
- AssayPeptide Screening 0.1% TFA
- 8.45 mg (± 0.04 mg)
- PurityPeptide Screening 0.1% TFA
- 99.4%
- Identity (FTIR)Peptide Screening 0.1% TFA
- 971 (± 5)
- Identity (RT)Retention time
- 0.997 (± 0.005)
- Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
- 0.012 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: Somatotropin
Authoritative database context for the parent human growth-hormone sequence.
PubChem · View source ↗Habibullah MM, Mohan S, Syed NK, et al. · 2022
Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
Primary in-vitro study using HGH Fragment 176-191.
Drug Design, Development and Therapy · 10.2147/dddt.s367586 View source ↗Heffernan MA, Thorburn AW, Fam B, et al. · 2001
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Primary experimental study of a modified growth-hormone C-terminal fragment.
International Journal of Obesity and Related Metabolic Disorders · 10.1038/sj.ijo.0801740 View source ↗



